The clinical landscape of managing patients with CKD

The clinical landscape of managing patients with CKD
10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada
  • Overview

    ISN-WCN 2019 Prof. David Cherney explains the major mechanisms underlying the protective effects of SGLT2 inhibition, followed by effects of SGLT2 inhibitors in non-diabetic kidney disease and future trials.

  • Educational information

    This lecture by prof. David Cherney was part of a CME accredited symposium "SGLT2 inhibition in CKD: Discussing the key questions and evidence"

  • Faculty

    Prof. David Cherney - Associate Professor, Department of Medicine, University of Toronto, ON, Canada

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

    View our meeting report

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free